Enbrel Price Cap Blocked: One Ruling That Could Reshape States Drug Pricing

A federal judge just blocked Colorado's price cap on Amgen's Enbrel, and the preemption logic in the ruling could shut down state-level drug pricing legislation across the country.

Meanwhile, Casgevy's pediatric label drops to age two, Moderna's mRNA flu rally just crossed seventy percent in a month, and yesterday's broad pharma surge pushed J&J to an all-time high. It's Friday. Let's close it out.

Welcome to The Pharma Closeout for Friday, July 3rd, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Our top story. A federal court has halted Colorado's attempt to cap the price of Amgen's blockbuster Enbrel by roughly seventy percent. The judge granted a temporary injunction after finding Amgen is, quote, likely to be significantly harmed by enforcement. Amgen shares climbed three and a half percent on the news. Endpoints called it a first-of-its-kind case — a state trying to enforce a binding price ceiling on a patented drug and getting blocked by a federal injunction.

What carries weight is the reasoning. The judge ruled that federal patent law preempts state-level drug price caps and wrote that Amgen's motion must be granted under binding Federal Circuit precedent. That's not a narrow procedural win. If this framework holds on appeal, it reaches well beyond Enbrel and well beyond Colorado.

Colorado was the test case the industry was watching. Its affordability review board had been the most aggressive in the country — the one that actually set a binding upper payment limit on a specific branded drug. Multiple other states have been building similar frameworks. This ruling tells every one of them the legal path forward is narrower than the political appetite suggested.

The framework may not hold. The Federal Circuit precedent the judge relied on was built around manufacturing process and product design disputes — not state boards setting upper payment limits on finished drugs. No court has tested that extension. A different appellate panel could read the same cases and reach the opposite conclusion. The industry is celebrating a first-round win, but this is an untested doctrine applied to a novel fact pattern.

Fair distinction. The IRA's Medicare negotiation framework is entirely federal, so this ruling doesn't touch it. But states had positioned themselves as the complementary front — going after drugs and categories that federal negotiations wouldn't reach for years. If the preemption argument survives at the circuit level, it closes off one of the two mechanisms pricing reformers have been building.

The durability question plays out over the next twelve to eighteen months. The ruling comes from a judge who is, per the Colorado Sun, a Trump appointee currently in consideration for a Tenth Circuit seat. How the full circuit treats the preemption argument — and whether other federal courts follow — will separate a durable precedent from a one-off injunction.

The competitive read for anyone running pricing strategy in branded pharma: this ruling buys time. The appeal will determine whether it buys certainty.

Shifting to the deal and pipeline side. We owe you a story from earlier this week. On Wednesday, the FDA approved a supplemental label expansion for Vertex and CRISPR Therapeutics' Casgevy — bringing the eligible age down from twelve to two for sickle cell disease and transfusion-dependent beta thalassemia. CRSP surged over eight percent yesterday. Morgan Stanley doubled its price target. And the stock was separately added to the Russell Growth Index, with a ninety-day return now above twelve percent.

What clinicians will key on is the age-two threshold itself. You're intervening before cumulative vascular damage from repeated crises has reshaped the organ damage profile — a fundamentally different patient and a fundamentally different risk-benefit conversation with families. The FDA also granted a Critical Need Pediatric Voucher under the pilot program, adding a transferable commercial asset to the expansion. Worth flagging — acting CBER Director Karim Mikhail signed off on this during a leadership transition at the review office. The agency is still executing.

A couple of callbacks. Orca Bio's Tregzi now has pricing at four hundred twenty-eight thousand dollars, completing the commercial picture on that approval. Celea, a PureTech spinout targeting IPF, raised a hundred eighty million dollars. Endpoints drew the comparison to Karuna — the PureTech spinout BMS acquired for fourteen billion. Also today, AstraZeneca committed up to $1.7 billion in milestones to CSPC for a kidney drug discovery collaboration — another data point in what's been a record stretch for cross-border China deals.

The Karuna comparison flatters. Karuna had late-stage psychiatric data in a large population. Celea is pre-pivotal in a fibrotic space where most programs that reach proof-of-concept still fail in pivotal trials. A hundred eighty million buys a legitimate shot, and PureTech's track record justifies some optimism — but this space has broken programs with stronger preclinical packages.

The broader picture underscores all of this. J&J hit a new all-time high yesterday at two-sixty-three, up three and a half percent. Gilead, AbbVie, Amgen — all up three to four percent. Intuitive Surgical up nearly six. Zoom out and drug manufacturers are up twenty-six percent year-to-date, biotech up twenty-two — both roughly doubling the S&P's eight and a half. That's a macro bid for the sector, not single-name catalysts.

On the regulatory side, the Moderna run tells a bigger story. mFLUSIVA — the mRNA flu vaccine — has driven the stock up more than seventy percent in a single month since VRBPAC voted nine-to-zero on June eighteenth. Two separate votes — adults fifty to sixty-four, then sixty-five and up. Both unanimous. FDA decision date: August fifth.

Here's the tension. If approved, mFLUSIVA would be the first mRNA flu vaccine to reach the market — a franchise Moderna has been building toward since COVID. And yet Wall Street's average price target implies forty-four percent downside from current levels. The stock rallied seventy percent on the advisory committee vote, and the sell-side consensus says it has nearly doubled past fair value. That disconnect either means the analysts haven't caught up — or the momentum trade has overshot. It resolves August fifth.

The regulatory path is as clean as it gets — nine-to-zero across both age cohorts leaves almost no room for a surprise. The harder question is commercial. Seasonal flu is a mature, price-sensitive market with entrenched egg-based manufacturing and decades of established distribution. The mRNA platform advantage is real, but platform advantage doesn't automatically convert to formulary share when payers are anchored to existing cost structures.

A pair of other regulatory items. FDA set a February twenty-eighth, twenty-twenty-seven target for Sarepta's Amondys 45 and Vyondys 53 — the accelerated-to-full-approval conversion for their DMD programs. And Sanofi's subcutaneous Sarclisa review was extended to July twenty-third.

Sarepta is the one to watch. A clean conversion reinforces the surrogate endpoint pathway in rare disease at a moment when that framework is under genuine scrutiny. If it goes the other direction, the reverberations reach every company banking on accelerated approval to get to market faster.

Looking ahead. We promised yesterday we'd have Scribe Therapeutics' IPO pricing — it hasn't landed. The S-1 is filed, no pricing date set. This remains one of the more closely watched gene-editing IPOs in the queue, and we'll have the read Sunday if it prices over the holiday weekend.

The forward calendar heading into Q3 sharpens fast. Moderna's FDA decision on August fifth is the next major catalyst. Sanofi's Sarclisa on July twenty-third. And the broader gene therapy question we flagged last month — whether regulatory throughput holds or stalls — keeps getting answered one program at a time.

Casgevy's pediatric expansion just answered it on the positive side. A few more approvals or label expansions in the next few weeks and the sector's risk profile heading into Q3 earnings looks materially different than it did a month ago.

We also owe you a follow on Roche's divarasib. The Phase 3 head-to-head data came in positive this week, but the full survival curves haven't hit a congress yet. When they do, that's when the competitive recalibration in KRAS-mutant lung cancer begins.

And that is your Pharma Closeout for Friday, July 3rd — what a week. The Enbrel ruling redrawing the state pricing map, Casgevy going pediatric at age two, Moderna's seventy percent mRNA flu rally, and a sector that keeps pulling away from the broader market. If someone on your team needs to be across this week in pharma, send them the feed — and if this briefing saves you time, follow us on Spotify and drop a rating.

Go enjoy the long weekend. We'll be back Sunday with the Weekend Closeout. See you then.